Clean Cells et Xenothera, deux acteurs d'Atlanpole Biothérapies dans la lutte contre le SARS-COV-2 La CDMO vendéenne Clean Cells a mis au point un test RT-qPCR dédié à la détection et la quantification du SARS-CoV-2 dans les substances actives ou les produits finis dédiés aux industries de la santé humaine…..
G&CTI, premier think tank indépendant sur les thérapies avancées Dans l’environnement actuel où les thérapies géniques et cellulaires apparaissent certes comme une véritable révolution médicale, mais où de nombreux défis éthiques, sociétaux, politiques, économiques se posent, la quête de réponses opérationnelles s’impose ! L’ensemble des acteurs (sociétés savantes, patients, industriels,…..
Agilent to Expand State-of-the-Art Manufacturing Capacity for Nucleic Acid-Based Therapeutics Agilent Technologies will expand its state-of-the-art production facility in Frederick, Colorado, that develops and manufactures “oligos,” which are short DNA and RNA molecules used to create nucleic acid-based therapeutics. Oligos hold the potential to be used in developing treatments for…..
Evotec-Secarna: new partnership in antisense oligonucleotide-based therapeutics The German companies Evotec and Secarna Pharmaceuticals have concluded a strategic partnership in the field of antisense oligonucleotide (ASO)-based therapeutics. Secarna, a global leader in discovering and developing next-generation ASO, combines its proprietary LNAplus™ platform with cutting edge third generation LNA-chemistry to generate…..
HexaPro: a new tool to speed up Covid-19 vaccine production ? Most coronavirus vaccine candidates train the human immune system to recognize the spike protein on the surface of the SARS-CoV-2 virus in order to fight infection. A scientific team at The University of Texas at Austin has successfully redesigned…..
Trend Chart On Innovative Bioindustries - July 2020, 29th FEATURE STORY GSK and CureVac announce strategic mRNA technology collaboration GSK and CureVac announced on July 20th the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies targeting…..
Trend Chart On Innovative Bioindustries - June 2020, 23rd FEATURE STORY ● Draft landscape of COVID-19 candidate vaccines This landscape document (published on June 16th) has been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product…..
Rigenerand receives regulatory approval for gene therapy production in Italy The italian biotech company Rigenerand has received received authorization from the Italian Medicine Authority (AIFA) to produce gene therapy medicinal products for clinical purposes. This approval enables Rigenerand to manufacture its own product, RR001, for the treatment of pancreatic cancer.…..
Trend Chart On Innovative Bioindustries - June 2020, 2nd FEATURE STORY ● Novartis snags EU nod for SMA gene therapy After a manufacturing-related delay, Novartis has won conditional approval in the EU for Zolgensma®, the one-time gene therapy to treat patients with a clinical diagnosis of SMA type 1 and…..
BioPharmAnalyses and OctopusyX BioConsulting are proud to announce the launch of their latest report:"AAV-based gene therapy Products: Ongoing Clinical Trials". This 205-page report provides you with a unique exhaustive overview of 116 ongoing trials for the treatment of 40 diseases (as of June 2020). More than 80 products from 49…..